Frontiers in Veterinary Science · 2023 · 21 citations · 47 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccinologyVirologyAnimal VirusesSubunit VaccinesSwine VaccinationVaccine Antigen DiscoveryVeterinary VaccinesViral VaccinesAdenoviral Vaccine VectorsAdenovirus VaccinesAntibodiesImmune Responses To African Swine Fever VirusLive Attenuated Swine VaccinesProtective AntigensRecombinant Antigen ExpressionSubunit Swine Vaccines
Introduction African swine fever virus (ASFV) is a pathogen of great economic importance given that continues to threaten the pork industry worldwide, but there is no safe vaccine or treatment available. Development of a vaccine is feasible as immunization of pigs with some live attenuated ASFV vaccine candidates can confer protection, but safety concerns and virus scalability are challenges that must to be addressed. Identification of protective ASFV antigens is needed to inform the development of efficacious subunit vaccines. Methods In this study, replication-incompetent adenovirus-vectored multicistronic ASFV antigen expression constructs that covered nearly 100% of the ASFV proteome were generated and validated using ASFV convalescent serum. Swine were immunized with a cocktail of the expression constructs, designated Ad5-ASFV, alone or formulated with either Montanide ISA-201™ (ASFV-ISA-201) or BioMize ® adjuvant (ASFV-BioMize). Results These constructs primed strong B cell responses as judged by anti-pp62-specific IgG responses. Notably, the Ad5-ASFV and the Ad5-ASFV ISA-201, but not the Ad5-ASFV BioMize ® , immunogens primed significantly ( p < 0.0001) higher anti-pp62-specific IgG responses compared with Ad5-Luciferase formulated with Montanide ISA-201™ adjuvant (Luc-ISA-201). The anti-pp62-specific IgG responses underwent significant ( p < 0.0001) recall in all the vaccinees after boosting and the induced antibodies strongly recognized ASFV (Georgia 2007/1)-infected primary swine cells. However, following challenge by contact spreaders, only one pig nearly immunized with the Ad5-ASFV cocktail survived. The survivor had no typical clinical symptoms, but had viral loads and lesions consistent with chronic ASF. Discussion Besides the limited sample size used, the outcome suggests that in vivo antigen expression, but not the antigen content, might be the limitation of this immunization approach as the replication-incompetent adenovirus does not amplify in vivo to effectively prime and expand protective immunity or directly mimic the gene transcription mechanisms of attenuated ASFV. Addressing the in vivo antigen delivery limitations may yield promising outcomes.
47
African Swine Fever Virus Isolate, Georgia, 2007
Rebecca J. Rowlands, Vincent Michaud, Livio Heath et al. · Emerging infectious diseases · 2008 · 590 citations · Full text
ICTV Virus Taxonomy Profile: Asfarviridae
Covadonga Alonso, Manuel V. Borca, Linda K. Dixon et al. · Journal of General Virology · 2018 · 484 citations · Full text
Alexandre Leitão, Clara Cartaxeiro, Ricardo Coelho et al. · Journal of General Virology · 2001 · 273 citations
Paulino Gómez‐Puertas, Fernando Rodrı́guez, Jose Oviedo et al. · Virology · 1998 · 267 citations